De novo post-diagnosis statin use breast cancer-specific and ove.pdf (143.34 kB)

De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.

Download (143.34 kB)
journal contribution
posted on 22.11.2019, 16:08 by Amelia Smith, Laura Murphy, Linda Sharp, Darran P. O'Connor, William M. Gallagher, Kathleen Bennett, Thomas I. Barron

BACKGROUND: Prior evidence suggests a role for statins in the management of cancer. However, the benefit of statin use in the adjuvant setting remains uncertain. This study investigates associations between statin use initiated after a breast cancer diagnosis and mortality.

METHODS: Women with stage I-III breast cancer were identified from the National Cancer Registry of Ireland (N=4243). Post-diagnostic statin initiators were identified from pharmacy claims data (N=837). Multivariate models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between de novo statin use and mortality.

RESULTS: The median duration of statin use was 6.7 years. No association was found between post-diagnostic statin use and breast cancer-specific (HR 0.88, 95% CI 0.66, 1.17) or all-cause mortality (HR 1.00, 95% CI 0.82, 1.21).

CONCLUSIONS: The results from our study suggest that initiating statin use after a diagnosis of stage I-III breast cancer is not associated with a reduction in breast cancer-specific mortality.

Logo branding

Categories

Keywords

Funding

We would like to thank the NCRI and the Irish Health Services Executive PCRS for providing access to the data upon which this study was based. In particular, we are grateful to the Data Team at the NCRI for linking the data sets, and Dr Sandra Deady and Mr Christopher Brown for preparing these for analysis. The interpretation and reporting of these data are the responsibility of the authors and should in no way be seen as the official policy or interpretation of the NCRI or the Irish Health Services Executive PCRS. This work was supported by the Irish Cancer Society Collaborative Cancer Research Centre BREAST-PREDICT (CCRC13GAL to WMG, KB, DOC and TIB) and the Health Research Board Ireland (ICE20119 to KB and LS). LM and AS are funded by the Irish Cancer Society Collaborative Cancer Research Centre BREAST-PREDICT (CCRC13GAL). TIB was funded by the Health Research Board Ireland (ICE20119).

History

Comments

This article is also available at http://www.nature.com/bjc/journal/v115/n5/pdf/bjc2016232a.pdf

Published Citation

Smith A, Murphy L, O'Connor D, Gallagher WM, Bennett K, Barron TI. De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer. British Journal of Cancer. 2016;115(5):592-598. [Epub 2016 Aug 2]

Publication Date

02/08/2016

Publisher

Nature Publishing

PubMed ID

27482648

Exports

Logo branding

Categories

Keywords

Exports